A. Gueler, A. Moser, and A. Calmy,

C. Swiss and . Study, Swiss National Cohort. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population, AIDS, vol.31, pp.427-463, 2017.

A. Therapy-cohort and C. , Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet HIV, vol.4, pp.349-56, 2017.

P. Morlat, C. Roussillon, and S. Henard,

. Anrs-en20-mortalité, Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS, vol.28, pp.1181-91, 2000.

C. J. Smith, L. Ryom, and R. Weber, Trends in underlying causes of death in people with HIV from, Lancet, vol.384, pp.241-249, 1999.

L. Garvey, V. Surendrakumar, and A. Winston, Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy, HIV Clin Trials, vol.12, pp.333-341, 2011.

R. K. Heaton, D. B. Clifford, and F. Dr, HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study, Neurology, vol.75, pp.2087-96, 2010.

K. R. Robertson, M. Smurzynski, and T. D. Parsons, The prevalence and incidence of neurocognitive impairment in the HAART era, AIDS, vol.21, pp.1915-1936, 2007.

L. A. Cysique, F. Vaida, and S. Letendre, Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy, Neurology, vol.73, pp.342-350, 2009.

N. Sacktor, R. L. Skolasky, and E. Seaberg, Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study, Neurology, vol.86, pp.334-374, 2016.

N. F. Crum-cianflone, D. J. Moore, and S. Letendre, Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons, Neurology, vol.80, pp.371-380, 2013.

M. Smit, K. Brinkman, and S. Geerlings,

C. Athena-observational, Future challenges for clinical care of an ageing population infected with HIV: a modelling study, Lancet Infect Dis, vol.15, pp.810-818, 2015.

J. A. Mccutchan, J. A. Marquie-beck, and C. A. Fitzsimons, Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder, Neurology, vol.78, pp.485-92, 2012.

R. K. Heaton, D. R. Franklin, and R. Deutsch, Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study, Clin Infect Dis, vol.60, pp.473-80, 2015.

C. Dufouil, L. Richert, and R. Thiébaut,

. Anrs-co3-aquitaine-study and . Group, Diabetes and cognitive decline in a French cohort of patients infected with HIV-1, Neurology, vol.85, pp.1065-73, 2015.

E. J. Wright, B. Grund, and K. Robertson, INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons, Neurology, vol.75, pp.864-73, 2010.

J. Schouten, F. W. Wit, and I. G. Stolte,

A. Group, Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study, Clin Infect Dis, vol.59, pp.1787-97, 2014.

B. Ovbiagele and A. Nath, Increasing incidence of ischemic stroke in patients with HIV infection, Neurology, vol.76, pp.444-50, 2011.

A. Antinori, G. Arendt, and J. T. Becker, Updated research nosology for HIVassociated neurocognitive disorders, Neurology, vol.69, pp.1789-99, 2007.

I. Grant, D. R. Franklin, and R. Deutsch, Asymptomatic HIVassociated neurocognitive impairment increases risk for symptomatic decline, Neurology, vol.82, pp.2055-62, 2014.

R. J. Ellis, J. Badiee, and F. Vaida, CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy, AIDS, vol.25, pp.1747-51, 2011.

F. Bonnet, H. Amieva, and F. Marquant,

S. Cohort, Cognitive disorders in HIV-infected patients: are they HIV-related?, AIDS, vol.27, pp.391-400, 2013.

J. Mcdonnell, L. Haddow, and M. Daskalopoulou,

, Cognitive Impairment in People with HIV in the European Region Study Group. Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men, J Acquir Immune Defic Syndr, vol.67, pp.120-127, 2014.

J. T. Becker, L. Kingsley, and J. Mullen,

C. Multicenter and . Study, Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men, Neurology, vol.73, pp.1292-1301, 2009.

J. H. Cole, M. Caan, and J. Underwood, No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS (COBRA) project, Clin Infect Dis, vol.66, pp.1899-909, 2018.

M. Zins, M. Goldberg, and . Constances, The French CONSTANCES population-based cohort: design, inclusion and follow-up, Eur J Epidemiol, vol.30, pp.1317-1345, 2015.

C. Ouvrard, C. Berr, and C. Meillon, Norms for standard neuropsychological tests from the French CONSTANCES cohort, Eur J Neurol, vol.26, pp.786-93, 2019.

T. Mura, H. Amieva, and M. Goldberg, Effect size for the main cognitive function determinants in a large cross-sectional study, Eur J Neurol, vol.23, pp.1614-1640, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01355388

J. Schouten, T. Su, and F. W. Wit,

A. Study-group, Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy, AIDS, vol.30, pp.1027-1065, 2016.

M. Gisslén, R. W. Price, and S. Nilsson, The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?, BMC Infect Dis, vol.11, p.356, 2011.

A. J. Morin, G. Moullec, C. Maïano, L. Layet, J. L. Just et al., Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults, Rev Epidemiol Sante Publique, vol.59, pp.327-367, 2011.

M. Goldberg, A. Leclerc, and M. Zins, Cohort profile update: the GAZEL cohort study, Int J Epidemiol, vol.44, pp.77-77, 2015.

G. Guaraldi, G. Orlando, and S. Zona, Premature age-related comorbidities among HIV-infected persons compared with the general population, Clin Infect Dis, vol.53, pp.1120-1126, 2011.

A. N. Do, E. S. Rosenberg, and P. S. Sullivan, Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the Medical Monitoring Project and the Behavioral Risk Factor Surveillance System, PLoS One, vol.9, p.92842, 2014.

K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke et al., Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet, vol.380, pp.37-43, 2012.

E. J. Wright, B. Grund, and L. A. Cysique, International Network for Strategic Initiatives in Global HIV Trials START Study Group. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial, HIV Med, vol.16, issue.1, pp.97-108, 2015.

H. Coban, K. Robertson, and M. Smurzynski, Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen, AIDS, vol.31, pp.1565-71, 2017.

K. Goodkin, E. N. Miller, and C. Cox,

C. Multicenter and . Study, Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study, Lancet HIV, vol.4, pp.411-433, 2017.

L. J. Garvey, N. Pavese, and M. Politis, Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART, AIDS, vol.28, pp.67-72, 2014.

M. J. Nichols, T. M. Gates, and J. R. Soares, Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection, AIDS, vol.33, pp.55-66, 2019.

J. Underwood, J. H. Cole, and M. Caan, Gray and white matter abnormalities in treated human immunodeficiency virus disease and their relationship to cognitive function, Clin Infect Dis, vol.65, pp.422-454, 2017.